We believe the study of human health in real-world, everyday environments is necessary to advance knowledge and discovery.
We make this possible by providing customized body-worn monitoring and analysis solutions rooted in scientific foundations.
We enable the world’s best researchers to obtain the highest quality, real-world data and analyze it appropriately and accurately.
Since 2010 VivoSense has been helping clinical researchers analyze and interpret wearable sensor data to improve patient research and care.
VivoSense is innovating within the pharmaceutical clinical trial industry by developing new digital biomarkers using their proprietary VivoSense® software. The platform is designed to deliver real-world digital clinical measures from wearable sensors, which will help to advance patient-focused drug development and precision medicine for patients with cancer, Alzheimer’s, rare disease and other therapeutic indications. The technology allows rigorous interpretation of subtle shifts in human physiology through customized, body-worn monitoring and analysis solutions rooted in scientific foundations.
The company is working to realize the potential of novel measures and technologies in regulatory and medical decision making to leverage real-world data at scale, bringing life-saving treatments to the patients who need them most.
“Measures that are trusted and valued by all stakeholders are the foundation on which all other innovation in digital health must be based." ~ Dudley Tabakin, chief executive officer of VivoSense
VivoSense closed a $25 Series A financing in March of 2022. The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments (COAs). VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.
" title="Dudley Tabakin "
>Dudley is CEO and co-founder of VivoSense and a fervent believer in “good data” over “big data” in the development of digital clinical measures from wearable sensor technology. He has a background in sports and gait biomechanics and more than 10 years experience in wearable sensor data analytics.
" title="Tanja Dowe "
>Tanja is the CEO of Debiopharm Innovation Fund, an evergreen fund investing in digital health companies that transform patient journeys and pharmaceutical R&D. Prior to joining Debiopharm, Tanja was the Managing Partner of Innomedica Ltd, a boutique strategy and transaction consulting company in life sciences, and a founder/CEO of a market research agency BioSolutions INT.
" title="Chris Garabedian "
>Chris founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund which supports early stage companies with Series A investments across biotech, medtech and healthtech.
" title="Lance Myers "
>Lance has 20+ years experience in digital health and has held multiple executive leadership positions over the course of his career. He was the Founding CEO of VivoSense from 2010 - 2014. Since 2017 he has served as the Head of Data Science at Verily Life Sciences and also leads a cardiovascular innovations business unit.
